Latest News

EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
11 March 2008. EUSA Pharma Inc today announced that it has entered into a definitive agreement to acquire all the outstanding shares of Cytogen Corporation (NASDAQ: CYTO) for $22.6 million. To meet the acquisition consideration, and fund further investments, EUSA Pharma has concurrently raised over $50 million in an investment round, led by TVM Capital, an international venture capital firm.

Novel Rapydan® gains Marketing Authorisation in EU for the
Relief of Pain associated with Needle Puncture and Cannulation
25 February 2008. EUSA Pharma today announced that Rapydan® (70 mg lidocaine/70 mg tetracaine medicated plaster) has now received marketing authorisation in Sweden, the UK, Germany, the Netherlands, France, Spain, Austria, the Czech Republic, Greece, Ireland, Norway and Portugal following the completion of the European Mutual Recognition Procedure.

EUSA Pharma out-licences preclinical-stage human antibody
to GlaxoSmithKline for up to $44 million plus royalties
18 February 2008. EUSA Pharma today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales.

EUSA Pharma announces $30 million Debt Facility
12 December 2007. EUSA Pharma announces that it has entered into a $30 million debt facility offered by Merrill Lynch Capital.

EUSA Pharma announces successful conclusion of the EMR Procedure for Rapydan®
18 October 2007. EUSA Pharma announces the successful conclusion of the European Mutual Recognition Procedure for Rapydan®. The procedure completed successfully at the “day 90” target date of 9 October 2007.